Nature Medicine asks experts to explain the research priorities for the field of GLP-1 receptor agonists such as semaglutide, from sex differences to how they might treat addiction.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout

References
Yeo, Y. H. et al. Ann. Intern. Med. 177, 1289–1291 (2024).
Lincoff, A. M. et al. N. Engl. J. Med. 389, 2221–2232 (2023).
Jager, K. J. et al. Kidney Int 96, 1048–1050 (2019).
Perkovic, V. et al. N. Eng. J. Med. 391, 109–121 (2024).
Wang, W. et al. Ann. Intern. Med. 177, 1016–1027 (2024).
üthi, H. et al. eClinicalMedicine 68, 102429 (2024).
Quddos, F. et al. Sci. Rep. 13, 20998 (2023).
Celis-Morales, C. A. et al. Diabetes Care 45, 634–641 (2022).
Montero, A., Sparks, G., Presiado, M. & Liz Hamel, L. KFF https://go.nature.com/48FgF43 (10 May 2024).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
May, M. Seven unanswered questions about blockbuster weight-loss drugs. Nat Med 30, 3389–3391 (2024). https://doi.org/10.1038/s41591-024-03380-1
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-024-03380-1